SAHPRA registers Paxlovid, an anti-viral medicine for COVID-19
Pretoria, 30 January 2023 – The South African Health Products Regulatory Authori...
Pretoria, 30 January 2023 – The South African Health Products Regulatory Authori...
Pretoria, 2 December 2022 – The South African Health Products Regulatory Authori...
Pretoria, 2 December 2022 – With the establishment of the South African Health P...
Pretoria, 24 November 2022 – In the past year, the South African Health Products...
Pretoria, 23 November 2022 – On 6 April 2021, the Pretoria High Court issued a c...
22 November 2022 Embargo: Immediate release Pretoria, 22 November 2022 – T...
Pretoria, 4 November 2022 – The South African Health Products Regulatory Authori...
Pretoria, 4 November 2022 – The South African Health Products Regulatory Authori...
Pretoria, 10 October 2022 – The South African Health Products Regulatory Authori...
Pretoria, 5 October 2022 – The South African Health Products Regulatory Au...
UPDATE ON COVID-19 HEALTH PRODUCTS: SAHPRA registers the Covovax COVID-19 vaccin...
Pretoria, 12 September 2022 – On the 04th of August 2022, SAHPRA issued a ...
04 August 2022 On 31 March 2021, SAHPRA approved the use of the COVID-19 Vaccine...
Embargo: Immediate release Pretoria, 20 July 2022 – The South African Health Pro...
28 June 2022 The South African Health Products Authority (SAHPRA) is pleased to ...
Embargo: Immediate release Pretoria, 24 June 2022 – The South African Health Pro...
Embargo: Immediate release Pretoria, 23 June 2022 – SAHPRA has registered a new ...
07 June 2022 Embargo: Immediate release1. The COVID-19 vaccine LHC has been regi...
30 May 2022 Embargo: Immediate release Pretoria, 30 May 2022 – The use of ...
27 May 2022 Embargo: Immediate release On 7 May 2022, the South African Health P...